We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

BIOCRATES and Selexis Join Forces to Optimize High-yield Mammalian Cell Cultures


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BIOCRATES and Selexis Join Forces to Optimize High-yield Mammalian Cell Cultures"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
Austrian BIOCRATES Life Sciences AG and Swiss Selexis SA have entered into a co-development agreement to further increase drug substance yields from mammalian cell cultures. Because most protein therapeutics require specific post-translational modifications (e.g., glycosylation) to exert their full therapeutic efficacy, mammalian cell systems have become the standard for the manufacture of most pharmaceutical recombinant proteins.

The comparatively high costs of mammalian cell culture processes, coupled with their low yields, have spurred interest in the development of novel methods to optimize and boost specific productivity and titers of recombinant proteins. Wombat Capital Ltd. provided expert advisory services to BIOCRATES for this collaboration.

Selexis SA: Unique technologies for the rapid development of high-performance mammalian cell lines for research preclinical, clinical, and commercial production purposes

Swiss-based Selexis SA, a privately held biotech company, is dedicated to the development of innovative technologies and expert services that enable significant reductions in the time, effort, and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins. A number of CHO cell lines developed by Selexis have already been scaled up and tested in large bioreactors (up to 1,000 liters), where they have been found to maintain the same high levels of expression seen under experimental conditions. They have been used for the generation of clinical-grade materials (up to phase II clinical trials). The yield improvement, combined with the stability of the Selexis cell lines, have been translated into increased yields in large-scale production.

“Our partnership with Selexis provides us with a unique opportunity to cooperate with an industry expert in cell culture development and optimization—a highly promising application of metabolomics,” said Elgar Schnegg, Chief Executive Officer of BIOCRATES. “We are confident that metabolomics will help to further fine-tune the characteristics of the high-performance cell culture systems developed by Selexis.”
Advertisement